|
|
| Line 1: |
Line 1: |
| {{drugbox |
| |
| | IUPAC_name = ''N-(4-(4,5-dihydro-2-methylimidazo<nowiki>[4,5-d][1]</nowiki>benzazepin-<BR>6(1H)-yl)carbonyl)phenyl)-<BR>(1,1'-biphenyl)-2-carboxamide''
| |
| | image = Conivaptan structure.svg
| |
| | width = 202
| |
| | CAS_number = 210101-16-9
| |
| | ATC_prefix =
| |
| | ATC_suffix =
| |
| | PubChem = 151171
| |
| | DrugBank =
| |
| | C=32 | H=26 | N=4 | O=2
| |
| | molecular_weight = 498.583
| |
| | bioavailability = N/A
| |
| | protein_bound =
| |
| | metabolism =
| |
| | elimination_half-life =
| |
| | excretion =
| |
| | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| |
| | pregnancy_US = <!-- A / B / C / D / X -->
| |
| | pregnancy_category =
| |
| | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S8 -->
| |
| | legal_UK = <!-- GSL / P / POM / CD -->
| |
| | legal_US = <!-- OTC / Rx-only -->
| |
| | legal_status =
| |
| | routes_of_administration = iv
| |
| }}
| |
| {{SI}}
| |
|
| |
|
| {{CMG}}
| |
|
| |
| ==Overview==
| |
| '''Conivaptan''' ('''vaprisol'''®, YM 087) is a non-peptide inhibitor of [[antidiuretic hormone]] (vasopressin). It was approved in 2004 for [[hyponatremia]] (low blood [[sodium]] levels) caused by [[syndrome of inappropriate antidiuretic hormone]] (SIADH), and there is some evidence it may be effective in [[heart failure]]. It is marketed by [[Astellas Pharma|Astellas Pharma Inc]].
| |
|
| |
| ==Mechanism of Action==
| |
| Conivaptan inhibits both isotypes of the [[vasopressin receptor]] ([[Arginine vasopressin receptor 1A|V1a]] and [[Arginine vasopressin receptor 2|V2]]). Effectively, it causes [[iatrogenic]] nephrogenic [[diabetes insipidus]].
| |
|
| |
| ==See also==
| |
| * [[Tolvaptan]]
| |
|
| |
| ==References==
| |
| {{Reflist|2}}
| |
|
| |
| [[Category:Hormonal agents]]
| |
| [[Category:Diuretics]]
| |
| [[Category:Drugs]]
| |
|
| |
| {{WH}}
| |
| {{WS}}
| |